In recent years, the Hyperparathyroidism Treatment Market has witnessed robust growth dynamics as healthcare providers and industry players focus on advanced therapeutic options. The latest Hyperparathyroidism Treatment Market report underscores rising demand for both surgical and pharmacological solutions, driven by increasing incidence rates and enhanced diagnostic capabilities.

Expert stakeholders leverage market research and market insights to navigate evolving market challenges and capitalize on emerging market opportunities across key regions. Analysts project sustained business growth underpinned by favorable regulatory frameworks and innovations in calcimimetic therapies. The interplay between market drivers and market restraints is shaping a competitive landscape where strategic collaborations and product diversification become critical for long-term industry size expansion.



Market size and Overview

The Global Hyperparathyroidism Treatment Market is estimated to be valued at USD 835.5 Mn in 2025 and is expected to reach USD 1350.4 Mn by 2032, growing at a compound annual growth rate (CAGR) of 7.1% from 2025 to 2032.

This industry size expansion is driven by rising prevalence of chronic kidney disease and Hyperparathyroidism Treatment Market in aging populations. Moreover, enhanced reimbursement policies in North America and Europe are fueling market revenue growth, while ongoing clinical trials for next-generation calcimimetics are set to broaden the market scope. Such market size and market report findings offer actionable market insights for stakeholders.



Key Takeaways:

- Dominating Region (2025): North America led the Hyperparathyroidism Treatment Market share, supported by the U.S. accounting for over 45% of global procedural revenue and advanced surgical infrastructure.

- Fastest Growing Region (2025): Asia Pacific recorded a 9.5% CAGR, with China's expansion of diagnostic labs driving improved market trends and treatment accessibility.

- Treatment Type Segment: Dominant sub-segment—surgical procedures (parathyroidectomy) remain preferred in leading academic medical centers. Fastest-growing sub-segment—calcimimetics, with Amgen's Parsabiv posting an 18% year-on-year revenue jump in Europe in 2025.

- Distribution Channel Segment: Dominant—hospital pharmacies. Fastest growing—online pharmacies, exemplified by Roche's direct-to-patient distribution pilot launched in late 2024.

- End-User Segment: Dominant—hospitals due to established surgical units. Fastest growing—ambulatory surgical centers, guided by Pathalys Pharma's network expansion in Southeast Asia.



Market Key Trends

One of the most significant market trends shaping the Hyperparathyroidism Treatment Market in recent years is the rapid adoption of minimally invasive robotic-assisted parathyroidectomy procedures. Following the FDA clearance of the Pathalys Robotic-Assisted Parathyroid Platform in June 2024, global robotic parathyroidectomies surged by over 22% in 2024 compared to 2023. This shift is reinforced by clinical data from a 2025 multicenter study which reported a 30% reduction in operative time and a 25% decrease in hospital stay for patients undergoing robotic procedures versus conventional surgery.

The trend is propelling increased capital investment by leading hospitals in North America and Europe, driving overall market revenue growth and bolstering market share for device manufacturers. Moreover, this innovation aligns with broader industry trends toward precision surgery and digital integration, where market drivers such as improved patient outcomes and policy support for value-based care models are converging to expand the market scope and influence future market forecast scenarios. According to a 2025 health economics study, hospitals allocated close to 12% of surgical technology budgets to robotic platforms, indicating a strategic market growth strategy.



Key Players:

Major market companies in the Hyperparathyroidism Treatment Market include Pathalys Pharma, Amgen, Takeda Pharmaceutical, Sanofi, Roche, Novartis, Pfizer, Bayer, Eli Lilly, Johnson & Johnson, GlaxoSmithKline, Abbott, Bristol-Myers Squibb, Merck & Co., and AstraZeneca.

In 2024, Amgen entered a strategic partnership with leading U.S. hospital networks to accelerate the rollout of next-generation calcimimetic therapies, resulting in a 15% increase in treatment adoption across participating institutions. In early 2025, Sanofi expanded its manufacturing footprint with a new facility in Singapore, boosting global production capacity of vitamin D analogs by 20%. Additionally, Roche launched a digital patient monitoring platform in Q2 2025, improving post-surgical compliance rates by 30% in initial pilot programs.



FAQs

1. Who are the dominant players in the Hyperparathyroidism Treatment Market?

Major players include Pathalys Pharma, Amgen, Takeda Pharmaceutical, Sanofi, Roche, Novartis, Pfizer, Bayer, and others leading in surgical devices and calcimimetic therapies.



2. What will be the size of the Hyperparathyroidism Treatment Market in the coming years?

The market is projected to grow from USD 835.5 Million in 2025 to USD 1350.4 Million by 2032, reflecting a CAGR of 7.1% driven by innovative products and expanding treatment access.



3. Which end-user segment has the largest growth opportunity?

Ambulatory surgical centers are expected to register the fastest growth, fueled by lower procedural costs and specialist networks expanding minimally invasive parathyroidectomy services.



4. How will market development trends evolve over the next five years?

The market forecast indicates a shift toward precision surgery and digital health integration, underpinned by regulatory support and reimbursement updates for robotic-assisted procedures.



5. What is the nature of the competitive landscape and challenges in the Hyperparathyroidism Treatment Market?

Competition is centered on technological innovation and portfolio diversification, while challenges include high R&D costs, pricing pressures, and navigating evolving regulatory frameworks.



6. What go-to-market strategies are commonly adopted in the Hyperparathyroidism Treatment Market?

Key strategies involve strategic partnerships with healthcare providers, regional manufacturing expansions, direct-to-patient distribution channels, and digital solution launches to drive business growth.

‣ Get this Report in Japanese Language: 副甲状腺機能亢進症治療市場

‣ Get this Report in Korean Language: 부갑상선기능항진증치료시장  

‣ Read More Related Articles : Global Metagenomic Sequencing: Unlocking the Secrets of Microbial Communities

Author Bio:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163 )